Search

Pulmatrix Inc

Gesloten

1.62 -2.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.63

Max

1.6600000000000001

Belangrijke statistieken

By Trading Economics

Inkomsten

-244K

-1.2M

EPS

-0.321

Werknemers

2

EBITDA

-244K

-1.2M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.6M

6.1M

Vorige openingsprijs

4.03

Vorige sluitingsprijs

1.62

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jul 2026, 23:56 UTC

Cryptocurrency values rise as global equity markets approach $166 trillion amid mixed sentiment and geopolitical uncertainties.

26 jul 2026, 23:56 UTC

"Ethereum and Bitcoin rise amid mixed market sentiment as Japan shifts to expansionary fiscal policy and key economic data looms."

26 jul 2026, 23:56 UTC

"Ethereum Rises 4.2% Amidst Strong Global Equity Markets and Upcoming Key Economic Data Releases."

26 jul 2026, 23:56 UTC

Cryptocurrency gains amid cautious investor sentiment in global equities as markets brace for key economic data and Fed interest rate decision.

26 jul 2026, 23:52 UTC

Australia's RBA Trimmed Mean CPI Release on July 29, 2026, Expected to Impact Monetary Policy Amid Rising Trade Tensions and Cost-of-Living Concerns.

26 jul 2026, 23:52 UTC

Australia's Inflation Rate YoY Data Set for Release on July 29, 2026, with Forecasted Increase to 4.1%, Impacting Monetary Policy and Market Sentiment.

26 jul 2026, 23:51 UTC

Correlated Moves

EUR/CAD shows a slight increase in after-hours trading, reflecting volatility and aligning with a similar uptick in EUR/USD amid comparable macroeconomic factors.

26 jul 2026, 23:51 UTC

EUR/SEK shows notable weakness in after-hours trading, declining since Friday's close and reaching a session low amid unusual downward pressure.

26 jul 2026, 23:51 UTC

Macro News
Correlated Moves

Bitcoin prices have risen to $65,392, reflecting optimism amid speculation of reaching $180,000. Trade tensions could impact global markets, including cryptocurrencies.

26 jul 2026, 23:41 UTC

GBP/CAD advances slightly in after-hours trading, positioned near the lower end of its one-month range. No specific news was identified for the move.

26 jul 2026, 23:41 UTC

Upcoming U.S. Employment Cost Index report on July 31 to reveal key wage growth data amid rising inflation and consumer concerns over grocery prices.

26 jul 2026, 23:41 UTC

Employment Cost Index for Q2 2026 set to rise by 0.8%, signaling potential implications for inflation and Federal Reserve interest rate decisions.

26 jul 2026, 23:41 UTC

U.S. Employment Cost Index Benefits Data Set for Release on July 31, 2026, Amid Global Labor Market Dynamics and Inflation Concerns.

26 jul 2026, 23:41 UTC

Canada's preliminary monthly GDP report on July 31, 2026, is anticipated to reveal growth amid mixed economic signals and external risks.

26 jul 2026, 23:23 UTC

Upcoming PCE Price Index Release on July 30, 2026, Expected to Reflect Consumer Inflation Amid Rising Grocery Prices and Economic Pressures.

26 jul 2026, 23:23 UTC

U.S. PCE Price Index Expected to Rise 0.4% in June Amid Ongoing Inflation Concerns and Consumer Behavior Shifts

26 jul 2026, 23:23 UTC

U.S. Personal Spending MoM Data Release on July 30, 2026 Expected to Show 0.4% Growth Amid Rising Grocery Prices and Changing Consumer Habits.

26 jul 2026, 23:23 UTC

Core PCE Price Index MoM for June 2026 set to release on July 30, with a modest forecasted increase of 0.1%, as markets remain cautiously optimistic amid mixed equity performance and Fed policy discussions.

26 jul 2026, 23:23 UTC

US Personal Income MoM Data Release on July 30, 2026 Expected to Show Modest 0.3% Increase Amid Mixed Economic Signals

26 jul 2026, 23:23 UTC

U.S. GDP Price Index Forecasted to Rise 3.7% Amid Inflation Concerns Ahead of July Release

26 jul 2026, 23:23 UTC

U.S. Q2 2026 GDP Growth Rate Release Forecasts 2.3% Amid Cautious Market Sentiment and Rising Consumer Prices

26 jul 2026, 23:23 UTC

South Korea's July export growth expected to remain strong at 70.9% YoY amid market volatility and global uncertainties, with a report due August 1, 2026.

26 jul 2026, 23:13 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is crucial as it follows a surprising May deficit amid rising imports and declining exports.

26 jul 2026, 23:13 UTC

S&P/Case-Shiller Home Price Index Expected to Show Modest 0.8% YoY Growth Amid Cooling U.S. Housing Market and High Inflation Concerns

26 jul 2026, 23:11 UTC

Correlated Moves
News

Ethereum is rising during Sunday’s trading session, gaining alongside Bitcoin amid strong market activity and global developments influencing investor sentiment.

26 jul 2026, 23:11 UTC

Correlated Moves
News

Ethereum is advancing during Sunday’s session, supported by Bitcoin's upward movement. The asset is trading well above recent averages amid strong market activity.

26 jul 2026, 23:02 UTC

After-market trading for SGD/CHF shows an upward trend, gaining since Friday's close. It is currently 1.09% above its 20-day moving average.

26 jul 2026, 23:01 UTC

GBP/CHF moved higher during after-market hours, reflecting strong momentum near the upper end of its one-month range. No specific news was identified.

26 jul 2026, 23:01 UTC

Correlated Moves

GBP/HKD is trading higher in after-market hours, reflecting a cumulative return that peaked at 0.30%. The pair shows unusual strength amid recent EUR/USD gains.

26 jul 2026, 23:01 UTC

Brazil's Unemployment Rate Release on July 30 Expected to Show Continued Improvement Amid Economic Optimism and External Challenges.

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat